This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NS Wind Down Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NS Wind Down.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Life Sciences winstgroei	18.2%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Investors Give NanoString Technologies, Inc. (NASDAQ:NSTG) Shares A 58% Hiding

Dec 19

Take Care Before Jumping Onto NanoString Technologies, Inc. (NASDAQ:NSTG) Even Though It's 42% Cheaper

May 19

NanoString Technologies (NASDAQ:NSTG) Is Making Moderate Use Of Debt

Apr 14

Is It Too Late To Consider Buying NanoString Technologies, Inc. (NASDAQ:NSTG)?

Oct 27

NanoString, Visiopharm team up to develop workflows for spatial biology solutions

Oct 13

NanoString Technologies (NASDAQ:NSTG) Has Debt But No Earnings; Should You Worry?

Oct 05

An Intrinsic Calculation For NanoString Technologies, Inc. (NASDAQ:NSTG) Suggests It's 35% Undervalued

Aug 08

When Should You Buy NanoString Technologies, Inc. (NASDAQ:NSTG)?

Jun 27

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat NS Wind Down onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:NSTG.Q - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2023	162	-166	-136	-115	N/A
6/30/2023	144	-166	-157	-133	N/A
3/31/2023	132	-161	-159	-134	N/A
12/31/2022	127	-160	-152	-129	N/A
9/30/2022	135	-145	-139	-118	N/A
6/30/2022	143	-139	-126	-109	N/A
3/31/2022	145	-127	-104	-92	N/A
12/31/2021	145	-115	-99	-91	N/A
9/30/2021	139	-109	-90	-84	N/A
6/30/2021	134	-99	-82	-76	N/A
3/31/2021	122	-99	-89	-83	N/A
12/31/2020	117	-110	-89	-82	N/A
9/30/2020	118	-63	-103	-90	N/A
6/30/2020	117	-65	-103	-90	N/A
3/31/2020	124	-57	-101	-89	N/A
12/31/2019	126	-41	-97	-89	N/A
9/30/2019	119	-86	-88	-84	N/A
6/30/2019	117	-80	-79	-75	N/A
3/31/2019	111	-80	-68	-64	N/A
12/31/2018	107	-77	-59	-54	N/A
9/30/2018	112	-65	-55	-52	N/A
6/30/2018	110	-60	-54	-51	N/A
3/31/2018	120	-44	-57	-54	N/A
12/31/2017	115	-44	-56	-52	N/A
9/30/2017	105	-46	-51	-46	N/A
6/30/2017	102	-45	N/A	-39	N/A
3/31/2017	90	-51	N/A	-29	N/A
12/31/2016	86	-47	N/A	-6	N/A
9/30/2016	84	-44	N/A	-4	N/A
6/30/2016	75	-44	N/A	-8	N/A
3/31/2016	66	-45	N/A	-19	N/A
12/31/2015	63	-46	N/A	-43	N/A
9/30/2015	56	-49	N/A	-44	N/A
6/30/2015	53	-52	N/A	-49	N/A
3/31/2015	50	-54	N/A	-42	N/A
12/31/2014	48	-50	N/A	-38	N/A
9/30/2014	42	-46	N/A	-43	N/A
6/30/2014	38	-42	N/A	-38	N/A
3/31/2014	34	-36	N/A	-35	N/A
12/31/2013	31	-34	N/A	-31	N/A
9/30/2013	28	-33	N/A	-25	N/A
6/30/2013	25	-30	N/A	-22	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if NSTG.Q's forecast earnings growth is above the savings rate (2.4%).

Winst versus markt: Insufficient data to determine if NSTG.Q's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if NSTG.Q's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if NSTG.Q's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if NSTG.Q's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if NSTG.Q's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

NS Wind Down Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Price target decreased by 8.2% to US$9.64

Price target decreased by 12% to US$9.64

Price target decreased by 22% to US$12.86

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Recent updates

NS Wind Down Co. Files Form 15

NS Wind Down Co., Inc. Emerged from Bankruptcy

First Amended Disclosure Statement Approved for NanoString Technologies, Inc.

NanoString Technologies, Inc. announced delayed 10-Q filing

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

The Nasdaq Stock Market to Delist the Common Stock of Nanostring Technologies

NanoString Technologies, Inc. announced delayed annual 10-K filing

NanoString Technologies, Inc. announced delayed annual 10-K filing

Patient Square Capital, LP agreed to acquire Substantially all assets of global business operations from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $220 million.

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from NASDAQ Composite Index

NanoString Technologies, Inc.(NasdaqGM:NSTG) dropped from S&P Global BMI Index

Motion for Joint Administration Approved for NanoString Technologies, Inc.

Motion for Joint Administration Filed by NanoString Technologies, Inc.

NanoString Technologies, Inc. Filed for Bankruptcy

Nanostring Launches the CosMx 6,000 Plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

NanoString Technologies, Inc. Releases the First Public Dataset of the Whole Transcriptome Obtained At True Single-Cell Resolution on the CosMx Spatial Molecular Imager

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

NanoString Technologies Receives Non-Compliance Notice from Nasdaq

Investors Give NanoString Technologies, Inc. (NASDAQ:NSTG) Shares A 58% Hiding

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 8.2% to US$9.64

Price target decreased by 12% to US$9.64

NanoString Technologies, Inc. to Report Q3, 2023 Results on Nov 06, 2023

NanoString Technologies, Inc. Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

Nanostring Appoints Todd Garland as Chief Commercial Officer

New major risk - Share price stability

Price target decreased by 22% to US$12.86

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

NanoString Technologies, Inc. Reiterates Earnings Guidance for the Full Year 2023

Delaware District Court Permits NanoString Technologies, Inc.'s Counterclaims That 10x Genomics and Harvard Violated the Antitrust Laws

NanoString Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

10X Genomics, Inc. Files New Patent Litigation Against Nanostring Technologies, Inc. and Vizgen, Inc. in the European Unified Patent Court

Independent Director recently bought US$202k worth of stock

Take Care Before Jumping Onto NanoString Technologies, Inc. (NASDAQ:NSTG) Even Though It's 42% Cheaper

10X Genomics Wins Permanent Injunction Against Nanostring's CosMX Products

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NanoString Technologies, Inc. Updates Earnings Guidance for the Year 2023

Independent Director exercised options to buy US$86k worth of stock.

NanoString Technologies (NASDAQ:NSTG) Is Making Moderate Use Of Debt

CEO, President & Director exercised options and sold US$203k worth of stock

Independent Director recently bought US$123k worth of stock

Consensus EPS estimates fall by 17%

Full year 2022 earnings: EPS misses analyst expectations

NanoString Technologies, Inc. to Report Q4, 2022 Results on Feb 28, 2023

NanoString Technologies, Inc. Showcases Ultra High-Plex 6K RNA Single Cell Imaging at the 2023 Advances in Genome Biology and Technology

CEO, President & Director exercised options and sold US$60k worth of stock

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

NanoString Technologies, Inc. Provides Product and Service Revenue Guidance for the Fourth Quarter and Full Year 2022

CEO, President & Director recently bought US$499k worth of stock

NanoString Technologies, Inc Begins Commercial Shipments of CosMx Spatial Molecular Imager and AtoMx Spatial Informatics Platform

Price target decreased to US$17.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is It Too Late To Consider Buying NanoString Technologies, Inc. (NASDAQ:NSTG)?

NanoString Technologies, Inc. to Report Q3, 2022 Results on Nov 07, 2022

NanoString, Visiopharm team up to develop workflows for spatial biology solutions

NanoString Technologies (NASDAQ:NSTG) Has Debt But No Earnings; Should You Worry?

An Intrinsic Calculation For NanoString Technologies, Inc. (NASDAQ:NSTG) Suggests It's 35% Undervalued

Nanostring Technologies, Inc. Provides Revenue Guidance for 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$32.67

Now 23% undervalued after recent price drop

NanoString Technologies, Inc. to Report Q2, 2022 Results on Aug 04, 2022

When Should You Buy NanoString Technologies, Inc. (NASDAQ:NSTG)?

NanoString Unveils AtoMx Spatial Informatics Portal at the 2022 Advances in Genome Biology and Technology (AGBT) General Meeting

Nanostring Technologies, Inc. Announces Plans to Commercially Unveil the Cosmx™ Spatial Molecular Imager